NCI

National Clinical Trials Network

Study Chair:

Study Co-chair:

MD, PhD

Jennifer M. Johnson,


Aarti Bhatia, MD, MPH





For Patients with Recurrent/Metastatic Head and Neck Cancer EA3202 Available Through ECOG-ACRIN Cancer Research Group A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atazolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition

Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent /Metastatic Head and Neck Cancers




Protocol Information

ECOG-ACRIN Operations-Boston: 857-504-2900, <u>http://ecog-acrin.org</u> (Member Login)

Please Enroll Your Eligible Patients!

Schema





Phase III sample size = 214